Baseline patient characteristics
| . | . | Median/number . | Range/percent . |
|---|---|---|---|
| Age (y) | 64 | 35-79 | |
| Sex | Male | 11 | 55% |
| Female | 9 | 45% | |
| Lymphoma histology | FL | 19 | 95% |
| MZL | 1 | 5% | |
| Stage at diagnosis | I | 0 | 0% |
| II | 3 | 15% | |
| III | 6 | 30% | |
| IV | 11 | 55% | |
| Grade at diagnosis (for patients with FL, n = 19) | 1-2 | 15 | 75% |
| 3A | 4 | 20% | |
| FLIPI at diagnosis (for patients with FL, n = 19) | 0-2 | 13 | 65% |
| 3+ | 6 | 30% | |
| Prior lines of therapy | 0 | 0 | 0% |
| 1 | 13 | 65% | |
| 2 | 3 | 15% | |
| 3 | 1 | 5% | |
| 4 | 1 | 5% | |
| 5 | 2 | 10% | |
| Prior therapy | Anti-CD20 | 14 | 70% |
| Chemotherapy | 10 | 50% | |
| PI3K inhibitor | 1 | 5% | |
| Lenalidomide | 1 | 5% | |
| Radiation | 5 | 25% | |
| Investigational agents | 6 | 30% |
| . | . | Median/number . | Range/percent . |
|---|---|---|---|
| Age (y) | 64 | 35-79 | |
| Sex | Male | 11 | 55% |
| Female | 9 | 45% | |
| Lymphoma histology | FL | 19 | 95% |
| MZL | 1 | 5% | |
| Stage at diagnosis | I | 0 | 0% |
| II | 3 | 15% | |
| III | 6 | 30% | |
| IV | 11 | 55% | |
| Grade at diagnosis (for patients with FL, n = 19) | 1-2 | 15 | 75% |
| 3A | 4 | 20% | |
| FLIPI at diagnosis (for patients with FL, n = 19) | 0-2 | 13 | 65% |
| 3+ | 6 | 30% | |
| Prior lines of therapy | 0 | 0 | 0% |
| 1 | 13 | 65% | |
| 2 | 3 | 15% | |
| 3 | 1 | 5% | |
| 4 | 1 | 5% | |
| 5 | 2 | 10% | |
| Prior therapy | Anti-CD20 | 14 | 70% |
| Chemotherapy | 10 | 50% | |
| PI3K inhibitor | 1 | 5% | |
| Lenalidomide | 1 | 5% | |
| Radiation | 5 | 25% | |
| Investigational agents | 6 | 30% |
Baseline characteristics of the 20 patients evaluable for safety and efficacy. Median and range (for age) or count and percent of all patients (for all other characteristics) are reported.
FLIPI, follicular lymphoma international prognostic index; MZL, marginal zone lymphoma.